Literature DB >> 15383595

Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.

Agatha M Masemola1, Tumelo N Mashishi, Greg Khoury, Helba Bredell, Maria Paximadis, Tiyani Mathebula, Debra Barkhan, Adrian Puren, Efthyia Vardas, Mark Colvin, Lynn Zijenah, David Katzenstein, Rosemary Musonda, Susan Allen, Newton Kumwenda, Taha Taha, Glenda Gray, James McIntyre, Salim Abdool Karim, Haynes W Sheppard, Clive M Gray.   

Abstract

Characterization of optimal CTL epitopes in Gag can provide crucial information for evaluation of candidate vaccines in populations at the epicenter of the HIV-1 epidemic. We screened 38 individuals with recent subtype C HIV-1 infection using overlapping consensus C Gag peptides and hypothesized that unique HLA-restricting alleles in the southern African population would determine novel epitope identity. Seventy-four percent of individuals recognized at least one Gag peptide pool. Ten epitopic regions were identified across p17, p24, and p2p7p1p6, and greater than two-thirds of targeted regions were directed at: TGTEELRSLYNTVATLY (p17, 35%); GPKEPFRDYVDRFFKTLRAEQATQDV (p24, 19%); and RGGKLDKWEKIRLRPGGKKHYMLKHL (p17, 15%). After alignment of these epitopic regions with consensus M and a consensus subtype C sequence from the cohort, it was evident that the regions targeted were highly conserved. Fine epitope mapping revealed that five of nine identified optimal Gag epitopes were novel: HLVWASREL, LVWASRELERF, LYNTVATLY, PFRDYVDRFF, and TLRAEQATQD, and were restricted by unique HLA-Cw*08, HLA-A*30/B*57, HLA-A*29/B*44, and HLA-Cw*03 alleles, respectively. Notably, three of the mapped epitopes were restricted by more than one HLA allele. Although these epitopes were novel and restricted by unique HLA, they overlapped or were embedded within previously described CTL epitopes from subtype B HIV-1 infection. These data emphasize the promiscuous nature of epitope binding and support our hypothesis that HLA diversity between populations can shape fine epitope identity, but may not represent a constraint for universal recognition of Gag in highly conserved domains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383595     DOI: 10.4049/jimmunol.173.7.4607

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Extensive HLA class I allele promiscuity among viral CTL epitopes.

Authors:  Nicole Frahm; Karina Yusim; Todd J Suscovich; Sharon Adams; John Sidney; Peter Hraber; Hannah S Hewitt; Caitlyn H Linde; Daniel G Kavanagh; Tonia Woodberry; Leah M Henry; Kellie Faircloth; Jennifer Listgarten; Carl Kadie; Nebojsa Jojic; Kaori Sango; Nancy V Brown; Eunice Pae; M Tauheed Zaman; Florian Bihl; Ashok Khatri; Mina John; Simon Mallal; Francesco M Marincola; Bruce D Walker; Alessandro Sette; David Heckerman; Bette T Korber; Christian Brander
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

3.  Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals.

Authors:  Sanjay Mendiratta; Madhu Vajpayee; Uma Malhotra; Shweta Kaushik; Lalit Dar; Kamalika Mojumdar; Neeraj Kumar Chauhan; Vishnubhatla Sreenivas
Journal:  Med Microbiol Immunol       Date:  2008-11-05       Impact factor: 3.402

4.  Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses.

Authors:  Rebecca Axelsson-Robertson; Frank Weichold; Donata Sizemore; Markus Wulf; Yasir A W Skeiky; Jerry Sadoff; Markus J Maeurer
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

5.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 7.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15

8.  Dynamic correlation between CTL response and viral load in primary human immunodeficiency virus-1 infected Koreans.

Authors:  Gab Jung Kim; Hak Sung Lee; Kee-Jong Hong; Sung Soon Kim
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

9.  The immunodominant influenza A virus M158-66 cytotoxic T lymphocyte epitope exhibits degenerate class I major histocompatibility complex restriction in humans.

Authors:  Joanna A L Choo; Jingxian Liu; Xinyu Toh; Gijsbert M Grotenbreg; Ee Chee Ren
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

10.  Salim "Slim" Abdool Karim: attacking AIDS in South Africa. Interview by Amy Maxmen.

Authors:  Salim Abdool Karim
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.